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Background: To assess the relationship between dosimetric parameters and the quality of life (QL) outcomes of
patients with low-intermediate-risk localised prostate cancer (LPC) treated with low-dose-rate brachytherapy (LDR-BT).
Materials and methods: We evaluated the participants in two consecutive prospective studies of the QL of patients
treated with LDR-BT for LPC. QL was evaluated by means of a patient-completed questionnaire assessing non functional
[physical (PHY) and psychological (PSY) well-being, physical autonomy (POW), social relationships (REL)] and functional
scales [urinary (URI), rectal (REC), and sexual (SEX) function]; a scale for erectile function (ERE) was included in the second
study. Urethra (D10≤ 210 Gy) and rectal wall constraints (V100≤ 0.5 cc) were used for pre-planning dosimetry and were
assessed with post planning computerized tomography one month later for each patient.
Results: QL was assessed in 251 LPC patients. Dosimetry did not influence the non-functional scales. As expected, a
progressive impairment in sexual and erectile function was reported one month after LDR-BT, and became statistically
significant after the third year. Rectal function significantly worsened after LDR-BT, but the differences progressively
decreased after the 1-year assessment. Overall urinary function significantly worsened immediately after LDR-BT and
then gradually improved over the next three years. Better outcomes were reported for V100 rectal wall volumes of
≤ 0.5 cc and D10 urethra values of≤ 210 Gy.
Conclusions: The findings of this study show that dosimetric parameters influence only functional QL outcomes while
non-functional outcomes are only marginally influenced.
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Low-dose-rate brachytherapy (LDR-BT) via a permanent
implant is an established option for the radical treatment of
localized prostate cancer (LPC) [1], and leads to at least the
same disease control as other local treatments in low–and
intermediate-risk patients [2, 3]. Furthermore, it is a treat-
ment procedure that can be done as an out-patient* Correspondence: antonello.veccia@apss.tn.it
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creativecommons.org/publicdomain/zero/1.0/procedure or maximal one overnight stay with a low bur-
den of side effects and the possibility of preserving the pa-
tients’ quality of life (QL). The side effects are mainly
related to the irradiation of the rectal wall and urethra, and
are usually transient provided that the patients are ad-
equately selected and specific dosimetric parameters are
respected [4]. The impact of LDR-BT on the QL has been
extensively assessed in a number of prospective studies;
Van Gellekom et al. and Vordermark et al. demonstrated
that most of the symptoms resolve within the first year after
implantation and reach a steady state by three years [5, 6].ticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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have been involved in two consecutive prospective stud-
ies aimed at assessing their QL: the first evaluated only
patients treated with LDR-BT and the final results were
published in 2006 [7]; the second (comparing the QL of
patients treated with LDR-BT or radical prostatectomy)
enrolled patients until July 2010 and is still in its long-
term follow-up phase, although the preliminary results
have been reported [8]. Despite the clear relationship be-
tween dosimetric parameters and the entity of side ef-
fects [9, 10], only a few studies have evaluated their
impact on the patients’ QL after LDR-BT [4–6].
The aim of this study was to describe the relationship
between dosimetric parameters and QL outcomes using
QL data relating to three years after LDR-BT.Materials and methods
Patients
Between May 2000 and June 2010, we used LDR-BT to treat
a consecutive series of 494 patients with LPC (median age
66 years), all of whom had a histopathological diagnosis of
prostate cancer based on a needle biopsy. The staging proce-
dures included a digital rectal exam, transrectal ultrasonog-
raphy, abdominal computed tomography (CT), a bone scan,
chest radiography, and PSA determination. No evidence of
distant or nodal metastases was required, PSA levels had to
be <15 ng/mL, Gleason score ≤7, clinical stage <T3 for im-
plant as monotherapy. The National Comprehensive Cancer
Network (NCCN) risk class was low and intermediate risk
in 69 and 31 % of the cases, respectively.
The LDR-BT consisted of an I-125 permanent implant
with a delivered dose of 145 Gy as exclusive treatment.
Thirty-seven percent of the patients underwent short-
term pre-implant hormonal therapy, which consisted of
three-four months of androgen deprivation therapy for
cytoreduction in patients with large prostate volume or
obstructive symptoms.
Biochemical relapses were defined on the basis of the
Phoenix ASTRO Consensus Conference recommenda-
tions [11].LDR-BT technique
Patients were implanted with I-125 and pre-loaded needles
under fluoroscopy and transrectal ultrasonography. Pre-
planning procedures were performed intra-operatively after
spinal anesthesia: the prescribed dose to the CTV (prostate
+ 3 mm in lateral and anterior direction) was 145 Gy and
the dosimetric constraints were prostate V100 > 95 %, ur-
ethra D10 ≤ 210 Gy and rectal V100 ≤ 0.5 cc. These dosimet-
ric constraints were arbitrarily developed in our Hospital
but they strongly correlate with the post planning dosimetry
defining the good practice in prostate brachytherapy. In par-
ticular, we established V100 ≤ 0.5 cc as dosimetric constraintin ultrasound pre-planning phase and we maintained this
cut off value for post-planning assessment.
The post planning evaluation was made using comput-
erized tomography (CT) one month after implantation.
Prostate D90 (dose in Gy at 90 % of prostate volume) and
V100 (% of prostate volume with ≥145 Gy) of each patient
were reviewed and recorded, together with dose volume
histograms (DVH) of the organ at risk (OAR), rectum and
surrogate urethra based on ultrasound intraoperative im-
ages. Patients selection, dosimetric analysis and QL evalu-
ation were defined according to the reference guidelines
of the American Brachytherapy Society (ABS) [12, 13].
QL assessment
First study
Until 2004, we used a previously validated patient-filled
questionnaire used in a retrospective study of LPC patients
treated with external radiotherapy [7]. The questionnaire
consisted of 43 items grouped into seven subscales assessing
various QL domains: physical well-being (PHY), psycho-
logical well-being (PSY), physical autonomy (POW), social
relationships (REL), urinary function (URI), rectal function
(REC), and sexual function (SEX). Three items explored the
patients’ global perception of their QL, and two assessed
how the patients perceived the information given to them
concerning the disease and its treatment. A standardized
score ranging from 0 to 100 was obtained for each subscale:
higher non-functional (PHY, PSY, REL, POW) and sexual
scale scores indicate better function, whereas higher urinary
and rectal scale scores indicate greater impairment.
After they had given their oral consent, the patients were
asked to complete the questionnaire one week before and
one month after the LDR-BT implantation; the pre-LDR-
BT questionnaire was given to each patient by physicians
during the first visit and returned on the day of the LDR-
BT procedure; the post-LDR-BT questionnaire was given
by physicians during the first follow-up visit one month
after LDR-BT, and the patients were asked to return it by
mail within seven days. In the second phase of the study,
we also asked the patients to complete the questionnaire
yearly (they were contacted by mail or during the follow-
up visit). In an attempt to avoid confounding factors cap-
able of affecting the QL outcomes, we excluded the pa-
tients who had experienced a biochemical/clinical relapse
or developed a second cancer from the follow-up survey.
The patients who refused to complete the follow-up ques-
tionnaires were asked to explain the reasons.
Second study
The new study started in May 2005, and was designed to
assess the different impact of prostatectomy and LDR-BT
on QL [8]. The questionnaire was the same as that used in
the previous study although, in order to assess the sexual
domain in more detail, we added the items suggested by
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UCLA Prostate Cancer Index (UCLA-PCI) that were not
included in the previous questionnaire. Other items were
also added to make the QL assessment more precise: for
example, the new version distinguished stress incontin-
ence from incontinence at rest. The questionnaire con-
sisted of 64 items that were grouped into the seven
previous subscales and an additional erection subscale
(ERE). As in the first study a standardized score ranging
from 0 to 100 was obtained for each subscale: higher non-
functional (PHY, PSY, REL, POW) and sexual scale scores
indicate better function, whereas higher urinary and rectal
scale scores indicate greater impairment.
The new version of the questionnaire was validated in
the first 40 patients enrolled in the study, and its validity
and reliability was confirmed (data not shown). During
the study, the assessment time points for the patients
treated with LDR-BT were the same as in the previous
study: the yearly assessment was planned for the first
five years after implant.
Both questionnaire versions were used only in these
studies and were not validated elsewhere. These studies
were approved by the local Ethical Committee of Santa
Chiara Hospital in Trento.
Statistical analysis
For the purposes of the present analysis, we considered all
of the patients who did not experience disease progression
and filled at least three QL questionnaires (pre-LDR-BT,
post-LDR-BT, and 1-year questionnaire) as evaluable.
Moreover, we assessed QL data until the third year after
LDR-BT. The General Linear Model (GLM) for repeated
measures was used to compare the scores at the different
assessment times, and Bonferroni’s post hoc test was used
to assess the statistical significance of the differences.
A more than 10 % change in the scores over time con-
stitutes a clinically meaningful difference according to
the recommendations of Osoba et al. [14].
The QL outcomes were stratified based on the extent to
which the dosimetric constraints of intraoperatively pre-
planned transrectal ultrasonography had been respected at
1 month post planning CT: D10 urethra dose (≤210 Gy vs
>210 Gy), V100 as a percentage of the prostate volume
enclosed by the prescription isodose (≤90 % vs 91-95 % vs
>95 %), and V100 rectal wall volume (≤0.5 cc vs >0.5 cc).
To avoid the confounding effect of hormonal manipulation
of sexuality scales (SEX and ERE), patients who were re-
ceiving hormonal treatment before LDR-BT were excluded
from the analysis of sexual outcomes. In addition, in asses-
sing the urinary outcomes we stratified the patients ac-
cording to the baseline urinary function status defined
according to URI scale values: poor (a URI score of ≥15;
more symptomatic patients) vs good (a URI score of <15;
less symptomatic patients). This cut off was obtainedthrough a series of questions including frequency of urin-
ation, the need to urinate at night, the presence of
hematuria, difficulty in initiating urination, urine leakage
with effort and at rest, difficulty in holding back urine, jet
urine reduced in strength or intensity, pain when urinat-
ing. Furthermore, the analyses were separately performed
in the patients enrolled in the two studies in order to
evaluate potential impact due to the different instrument
adopted.
Results
Data concerning QL outcomes were available from 251
patients (128 from the first study and 123 from the sec-
ond): all the assessed patients received LDR-BT as exclu-
sive treatment and filled at least pre-LDR-BT, post-LDR-
BT, and 1-year questionnaires. One hundred seventy-
three patients (69 %) and 97 patients (37 %) were evalu-
able for 2-year and the 3-year assessment, respectively.
Data about all QL outcomes were available in all filled
questionnaires.
The median age was 66 years (range 49–77).
Non-functional scales (PHY, PSY, REL, POW) (Fig. 1)
There was a statistically significant difference in the
PHY scale between the pre-implant score and one-
month post-implant score (p = 0.049), but it was lost in
the following three years.
In PSY scale no statistically significant differences from
baseline were observed one month post LDR-BT; however
we observed an improvement which became significant at
one year (p = 0.017) and at the following assessment time
points, without returning to the baseline level. One year
after LDR-BT better PSY scores were observed in patients
with V100 prostate volume of 91-95 % (p = 0.028) and
V100 rectal wall volume ≤ 0.5 cc (p = 0.014).
There was no statistically significant difference from
baseline in the REL scale after one, two or three years, but
the difference was of borderline significance one month
post-implantation (p = 0.056).
There was no significant difference from baseline in
the POW scale one month after LDR-BT or later.
The results were confirmed assessing separately the
patients enrolled in the two studies (data not shown).
Physical function scales (SEX, ERE, URI, REC)
(Figs. 2 and 3)
Progressively impaired sexual function was reported
from one month after LDR-BT, despite the differences
became statistically significant after two years (p = 0.034)
and remained significant until the third year (p = 0.017).
In the subgroup receiving prostate V100 > 95 %, the im-
pairment was always statistically significant from the
first year to the third year: p = 0.001 after one year, p =
0.032 after two years, and p = 0.002 after three years.
Fig. 1 outcomes of non functional scales (median values) where a: urethra D10≤ 210 Gy, b: urethra D10 > 210 Gy, c: rectal wall V100≤ 0.5 cc,
d: rectal wall V100 > 0.5 cc, e: prostate ≤90 %, f: prostate 91-95 %, g: prostate >95 %, h: results not stratified by the DVH (* p < 0.05)
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Fig. 2 outcomes of sexual function-related scales (median values in patients not receiving hormone therapy) where a: urethra D10 ≤ 210 Gy, b:
urethra D10 > 210 Gy, c: rectal wall V100≤ 0.5 cc, d: rectal wall V100 > 0.5 cc, e: prostate ≤90 %, f: prostate 91-95 %, g: prostate >95 %, h: results
not stratified by the DVH (* p < 0.05, ** p < 0.001, *** p < 0.0001)
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Fig. 3 outcomes of other function scales (median values) where a: urethra D10≤ 210 Gy, b: urethra D10 > 210 Gy, c: rectal wall V100≤ 0.5 cc, d:
rectal wall V100 > 0.5 cc, e: prostate ≤90 %, f: prostate 91-95 %, g: prostate >95 %, h: results not stratified by the DVH (* p < 0.05, ** p < 0.001,
*** p < 0.0001)
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SEX scale was impaired, despite the greatest effect was
observed at the 1-month assessment (p = 0.008).
All of the patients reported a clear decrease in the
ERE scale after LDR-BT (p = 0.0001): this impairment
remained significant until the third year (p = 0.0001).
The greatest impairment was observed in patients with
D10 urethra dose >210 Gy, V100 rectal wall volume
≤0.5, and V100 prostate volume >95 %.
The REC scale significantly worsened after LDR-BT (the
mean REC score increased from 6.3 to 12.1; p = 0.0001),
but the difference progressively decreased from the time
of the 1-year assessment, and was no longer significantly
different from baseline after three years (p = 0.367).
Regardless of the statistical significance, the most rele-
vant data concerned post-plan V100 rectal wall volume:
when it was ≤0.5 cc (in accordance with the pre-planned
constraints), the QL worsened between baseline to one
month after LDR-BT (from 6.3 to 12.2), and then pro-
gressively improved until it returned to near-baseline
levels after three years (the 1-, 2- and 3-years scores
were respectively 9.1, 8.7 and 6.9). When V100 rectal
wall volume was >0.5, QL worsened between baseline
and one month after LDR-BT (from 6.3 to 10.0) and the
score was maintained over the three years (Fig 3c, d).
The URI scale significantly worsened immediately after
LDR-BT: the mean score increased from 11.8 at baseline to
28.6 one month later, and then gradually improved over the
next three years although it always remained significantly
different from baseline (the 1-, 2- and 3-year scores were
respectively 22.8, 18.8 and 17.2; p = 0.0001). The worst im-
pairment was recorded in the patients with good baseline
urinary function, whose post-LDR-BT score was about four
times higher than the baseline score (25.7 vs 6.8) and
remained high over time (19.8, 18.4 and 15). The patients
with poor baseline urinary function showed a significant
worsening in the URI score one month after LDR-BT (34.7
vs 22), but this returned to baseline level after two years
(22.9) and remained there after three years (21.2). When
the post-plan dose at 10 % (D10) of urethra was ≤210 Gy
(in accordance with the pre-planned constraint), the QL
score worsened between baseline and one month later
(from 10.1 to 27.5), but then progressively improved over
the years and returned to near-baseline levels after three
years (1-, 2- and 3-year scores of respectively 17.8, 16.9 and
12.3). When D10 urethra was ≥210 Gy, the QL score wors-
ened between baseline and one month (from 10.1 to 29.0)
and never returned to baseline level (Fig. 3a, b). The results
were confirmed assessing separately the patients enrolled in
the two studies (data not shown).
Conclusions
To the best of our knowledge, this is the first study assessing
dosimetric parameters and their impact on all QL domainsafter LDR-BT, and the results show a substantial impact on
functional scales and a marginal effect on non-functional
scales.
Most of the previously published studies focused on treat-
ment side effects but did not comprehensively assess the im-
pact on the patients’ feelings or QL dimensions. A recent
study from Hannover University described a series of 186
consecutive patients, whose morbidity after I-125 brachy-
therapy was prospectively assessed using the International
Prostate Symptom Score (IPSS) and the IIEF-5 over a me-
dian follow-up of 30 months. All of the scores troughed
after six weeks and normalized after 24 months. The correl-
ation between segmental dosimetry and the scores at the dif-
ferent time points demonstrated that only the prostate base
scores remained statistically significant in multivariate re-
gression analyses at all time intervals (p <0.00) [15].
Allen et al. evaluated the relationship between urinary
morbidity after LDR-BT and urethral doses at the base-
line, mid-prostate, apical and urogenital diaphragm. The
study did not find any statistically significant influence
on IPSS at univariate or multivariate analysis [16].
Thomas et al. found that radiation dose at the urethral
base, larger prostate ultrasound planning volumes and
needle number predicted increased urinary toxicity fol-
lowing LDR-BT [17].
Vordermark et al. reported QL data in 74 low-risk
prostate cancer patients treated with permanent I-125
brachytherapy. The study demonstrated that both urin-
ary and bowel symptoms strongly correlated with pre-
treatment scores during the first year after the treat-
ment, suggesting the importance of screening patients
for baseline symptoms for treatment choice [6].
The most striking results of our study concerned phys-
ical function, particularly the rectal and urinary scales.
As expected, a progressive impairment in sexual and
erectile function was reported one month after LDR-BT,
and remained statistically significant after the third year. Ir-
radiation of the penile bulb is a considerable issue because
this organ is considered at risk for erectile damage [18]. As
this dosimetric parameter was not included in the pre-
operative planning evaluation, the lack of data is a limitation
in our study.
Rectal function significantly worsened after LDR-BT,
but gradually improved after the 1-year assessment and
was no longer significantly different from baseline after
three years (p = 0.367).
Regardless of statistical significance, the QL depends on
V100 rectal wall volume irradiation (≤ or > 0.5 cc). When
the percentage of rectal volume receiving ≥145 Gy was
≤0.5 cc, the QL worsened between baseline and one month
after LDR-BT, but progressively improved over the years,
and returned to baseline levels after three years; when rectal
V100 was > 0.5, the QL worsened between baseline and
one month, and never improved again (Fig. 3c, d).
Veccia et al. Radiation Oncology  (2015) 10:130 Page 8 of 8Urinary function significantly worsened immediately after
LDR-BT, but gradually improved over the next three years,
although the mean URI score was always significantly dif-
ferent from baseline. The subgroup analysis showed that
the patients with good baseline urinary function experi-
enced less improvement at long term follow up than those
with poor baseline urinary function: the former had a post-
LDR-BT URI score that was about four times higher than
baseline (25.7 vs 6.8) and remained higher over time,
whereas the latter showed a significant worsening one
month after LDR-BT (34.7 vs 22), but returned to baseline
level after two years (22.9) and maintained this level after
three years (21.2). Based on these findings, it seems that
brachytherapy can also be proposed to patients with a sub-
optimal urinary function.
The most interesting data concern the D10 urethra par-
ameter: when it was ≤210 Gy, the QL worsened between
baseline and one month after LDR-BT, but then progres-
sively improved and returned to near-baseline levels after
three years; when it was >210 Gy, the QL worsened be-
tween baseline and one month later, and never returned
to baseline levels (Fig. 3a, b).
The outcomes relating to the non-functional scales (PHY,
PSY, REL, POW) were usually not statistically significant.
The results are difficult to interpret, but suggest that LDR-
BT has only marginal effects on LPC patients’ QL.
Many studies have considered the relationships between
dosimetric parameters and biochemical outcomes or treat-
ment side effects after LDR-BT, but ours is the first to inves-
tigate the impact of post-planning dose volume histograms
on the QL. It provides further evidence that a good implant
and respect for the usual planning constraints on the rectum
and urethra are important factors for maintaining a good
QL degree.
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